Diagnostic challenge: Primary leptomeningeal melanoma with melanomatosis, illustrative case report.

doi:10.21203/rs.3.rs-2478033/v2

Download PDF

Case Report

Diagnostic challenge: Primary leptomeningeal melanoma with melanomatosis, illustrative case report.

https://doi.org/10.21203/rs.3.rs-2478033/v2

This work is licensed under a CC BY 4.0 License

Version 2

posted

You are reading this latest preprint version

Primary leptomeningeal melanoma is an extremely rare type of intracranial melanoma. It cannot be reliably distinguished from metastatic melanoma on neuroimaging and histopathological characteristics alone; its diagnosis is established only after exclusion of secondary metastatic disease from a cutaneous, mucosal or retinal primary. Prognosis is poor, partly due to its high rate of misdiagnosis. Herein, we report a case of a Primary Meningeal Melanoma of the skull base with Melanomatosis, in 31 years old man, mimicking Meningioma. Our aim is to highlight the diagnostic pitfalls and to discuss the histopathological differential diagnoses especially with other pigmented lesions of Central nervous system (CNS).

Meninge

Melanoma

differential diagnosis

Histopathology

The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma). Primary leptomeningeal melanoma is an extremely rare type of primary intracranial melanoma, with a global incidence of 1 case per 20 million individuals [1, 2]. It may be classified into two types based on the behavior of the tumor; one type invades the pia mater diffusely and spreads into the subarachnoid space, while the other causes nodular tumors [1].

Because of its rarity and aggressive behavior; it is often misdiagnosed and associated with a therapeutic failure.

We report the case of 31-years-old man, with no past medical history and no extracranial abnormality. He was admitted to the neurosurgery department for the management of an intracranial skull base tumor suggestive of a meningioma. On admission, the patient was experiencing signs of increased intracranial hypertension, and he reported a rapid deterioration of visual acuity causing bilateral blindness. He had no motor deficit.

Magnetic Resonance Imaging (MRI) scan showed a skull base tumor that was hypointense on T1, hyperintense on T2, with regular and homogeneous contrast enhancement. The radiologist suggested an anterior skull base Meningioma, although atypical for the age of the patient (Fig. 1). A control Computed Tomography (CT) scan -performed before admission- demonstrated a rapid growth of the tumor, almost reaching double the initial volume over a 2 months period, with perilesional edema (Fig.1). This was clearly in favor of an aggressive behavior and questioning the suggested diagnosis of meningioma.

Surgical records reported a dark and highly vascular extra-axial tumor with a dural attachment to the left anterior skull base. The dura mater underlying the tumor surface was blackened (Fig. 2). The tumor extended throughout the subarachnoid space and invaded the cerebral parenchyma. In front of this strange aspect, the surgeon evoked a Hemangioblastoma and could achieve a gross total resection with complete decompression of both optic nerves.

At pathological examination, the tumor was black, firm with irregular surface (Fig. 2c). Intra-operative smears revealed monomorphic and round tumor cells with basophilic characteristics. Some pigmented deposits were observed but at this stage the pathologist proposed the diagnosis of an undifferentiated round cell tumor (Fig. 3). Histologically, - after formalin fixation- the tumor was composed of hypercellular sheets, nests and spindled cells associated with many melanic deposits. The tumor cells had a prominent nucleoli and a moderate amount of eosinophilic cytoplasm. We did not observe a significant nuclear pleomorphism or numerous atypical mitoses; however, we noted foci of tumor necrosis (Fig. 3).

On immunohistochemistry (IHC), the neoplastic cells stained positively for melanoma antibody HMB45 and MelanA (Fig. 4); while they were negative for epithelial membrane antigen (EMA) and BRAF V600E. The Ki67 labelling index was 30 % in the highest proliferating areas.

Thus, the diagnosis of Meningeal Melanoma with Melanomatosis was made.

A diagnosis of primary Meningeal Melanoma was confirmed after careful dermatologic and ophthalmologic examination, which ruled out presence of cutaneous or choroidal melanoma.

The postoperative course was serious. The patient died due to ischemic complications.

Melanocytic cells are normally found in the meninges of the central nervous system (CNS). They are numerous only on the ventral aspect of the lower part of the medulla oblongata, and a slight pigmentation is macroscopically visible in this region [2]. Diffuse or circumscribed primary leptomeningeal melanocytic neoplasms derived from meningeal melanocytic cells are rare [3].

According to the 2021 edition of the World Health Organization (WHO) classification of tumors of the CNS, diffuse lesions are characterized by the involvement of large expanses of the subarachnoid space with or without focal nodularity. Based on whether the lesion has benign or malignant histological phenotype, it is called meningeal melanocytosis or meningeal melanomatosis, respectively [4].

Circomscribed neoplasms may be designated as melanocytomas if they are benign or melanomas if they are malignant. Intermediate-grade lesions are also designated as melanocytomas.

Usually, all meningeal melanocytic tumors strongly express PS100, Melan A, HMB45 and MITF [5].

On histology, meningeal melanoma is accompanied by marked cytological atypia, increased mitotic activity > 1,5 mitoses/mm2 and often demonstrated unequivocal invasion of the CNS parenchyma or coagulative necrosis. It may be composed of pleomorphic spindled or epitheloid cells and display variable cytoplasmic melanin and numerous mitotic figures [5].

Others meningeal melanomas –such as our case- are highly cellular and less pleomorphic and usually consisting of smaller, tightly packed spindle cells. This histological aspect can be a challenge for the pathologist and must be distinguished from melanocytoma which is a benign tumor and lack cytological atypia, necrosis and mitoses (on average < 0,5 mitoses/mm2, equating to <1mitosis/10 HPF of 0,5mm in diameter and 0, 2 mm2in area). Melanocytoma do not show invasion of CNS parenchyma. In the cases where a histological melanocytoma shows CNS invasion or increased mitotic activity (0,5-1,5 mitoses/mm2, equating to 1-3 mitoses/ 10 HPF of 0,5mm in diameter and 0,2 mm2in area) and no necrosis, the tumor is defined as Intermediate-grade Melanocytoma [5]. Cases of malignant transformation of melanocytoma into melanoma are described in the literature but are rare and occur especially after recurrence [6,7].

Through the WHO description, we deduce the value of tumor necrosis and mitotic activity to classify these tumors.

Another aspect of diagnostic difficulty encountered with meningeal melanoma is to confirm its primitive character and to distinguish it from other cerebral pigmented neoplasms.

Primary CNS melanoma is generally diagnosed following the exclusion of a primary cutaneous or mucosal/retinal melanoma, as differential histological diagnosis between primary and metastatic origins is often difficult [8, 9].

In addition of Meningeal Melanocytoma described above, the other differential diagnoses are represented by Meningioma which can have similar neuroradiologic findings and may mimic cerebral melanoma. The differential diagnosis is more difficult in some cases of meningioma with cells containing melanin pigment; in this case, the immunohistochemical positivity of Somatostatin Receptor 2a, EMA and Progesterone Receptor is in favor of meningioma [3].

The distinction between meningeal melanoma and other melanotic tumors of the central nervous system such as Melanotic schwannoma - which has a similar immuoprofile to that of melanoma - can be a challenge [3]. Melanotic schwannoma is favored over malignant melanoma if features psammoma bodies and adipose-like cells, has cells with benign or mildly atypical cytology, and demonstrates evidence of pericellular basement membrane synthesis [10].

In some cases, mutation analysis (including for GNAQ, GNA11PLCB4 and CYSLTR2) and methylation profiling are useful for recognizing meningeal melanoma as primary CNS tumor and discriminating them from another pigmented CNS tumor. Because of the limited number of primary leptomeningeal melanocytic lesions analyzed, other mutations are less well characterized [11].

The survival for melanoma diagnosis with leptomeningeal involvement is poor. It is known that there are no specific guidelines for the management of both the primary CNS melanomas and leptomeningeal melanomatosis as they are rarely seen. However, radiotherapy, especially after surgical resection of a primary tumour, systemic chemotherapy with agents such as dacarbazine, cisplatin, thalidomide or temozalamid or intrathecal therapy with methothraxate, cytarabine and sometimes immunmodulatory agents such as peginterferon alpha-2b have all been used as treatments [12, 13].

The prognosis and life expectancy for patients with primary leptomeningeal melanoma associated with melanomatosis is worse despite treatment. Most authors quote a median survival of less than one year [14].

Meningeal melanomas present poor prognosis, partly due to their high rate of misdiagnosis.This case highlights the diagnostic pitfalls encountered by the pathologist during the analysis of leptomeningeal melanocytic neoplasms. We insist on the importance of the histological interpretation to classify these tumors in the absence of clinical, radiological and immunohistochemical specificity.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING:

No external funding sources are relevant to this submission.

CONSENT FOR PUBLICATION:

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient.

DATA AVAIBILITY:

No new data were generated or analysed in support of this research.

1. Yunfeng M, Qiuping G and Senyang L. Intracranial malignant melanoma: a report of 7 cases. Oncology Letters 2015; 10: 2171-2175.

2. Helseth A, Helseth E and Unsgaard G. Primary meningeal melanoma. Acta Oncologica 1989; 28(1): 03-104,

3. Grecocrasto S, Soffietti R, Bradac GB and Boldorini R. Primitive cerebral melanoma: case report and review of the literature. Surg Neurol 2001; 55:163–168.

4. Garbacz T, Osuchowski M and Bartosik-psujek H. Primary diffuse meningeal melanomatosis – a rare form of meningeal melanoma: case report. BMC Neurol 2019; 19 (1): 271- 275.

5. Singh R, Wesseling P. Melanocytic tumours. In WHO Classification of Tumours Editirial Board: Central Nervous System Tumors. 5^th Edition. Lyon (France). IARC Press, 2021; 340–348.

6. Fulin W, Guangyu Q, Xin L, Xin S and Wei C. Malignant transformation of intracranial meningeal melanocytoma. Case report and review of the literature. Neuropathology 2011; 31, 414–420.

7. Wang F, Li X, Chen L, Pu X. Malignant transformation of spinal meningeal melanocytoma. Case report and review of the literature. J Neurosurg Spine 2007; 6: 451–454.

8. Tabassum A, Swati T, Tejpal G, Sreedhar E and Rakesh J. The diagnostic dilemma of primary central nervous system melanoma. Journal of Clinical Neuroscience 2010; 17: 1014–1017.

9. Ferraresi V, Ciccarese M, Zeuli M and Cognetti F. Central nervous system as exclusive site of disease in patients with melanoma: treatment and clinical outcome of two cases. Melanoma Res 2005; 15:467–469.

10. Borislav A A, Pauline MC and Lawrence JJ. Pathology of melanotic schwannoma. Arch Pathol Lab Med 2018; 142 (12): 1517–1523.

11. Melanie LO, Julian W, Carl BH, Alina K. Primary meningeal melanoma masquerading as neurofibromatosis type 2: Illustrative case. J Neurosurg Case Lessons 202; 2(20). doi: 10.3171/case21444.

12. Sabina A, Rahsan G, Nazire PA and al. Two cases of primary leptomeningeal melanomatosis mimicking subacute meningitis. The Neuroradiology Journal 2017; 0(00): 1–5.

13. Tarhini AA and Agarwala SS. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004; 16: 161‑166.

14. Simonsen TG, Gaustad JV and Rofstad EK. Bevacizumab treatment of meningeal melanoma metastases. J Transl Med 2020;18(13). https://doi.org/10.1186/s12967-020-02212-3.

No competing interests reported.

Download PDF

Version 2

posted

You are reading this latest preprint version

Diagnostic challenge: Primary leptomeningeal melanoma with melanomatosis, illustrative case report.

Status:

Version 2

Abstract

Figures

Introduction

Case

Discussion

Conclusion

Declarations

References

Additional Declarations

Status:

Version 2